David A. Siegel Eliem Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 94,900 shares of ELYM stock, worth $390,039. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94,900
Previous 114,000
16.75%
Holding current value
$390,039
Previous $468,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ELYM
# of Institutions
67Shares Held
49.5MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.82% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2.5MShares$10.3 Million0.01% of portfolio
-
Citigroup Inc1.61MShares$6.62 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.33MShares$5.47 Million0.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...